Can I get pregnant (or plan pregnancy) while taking secukinumab (Cosentyx)?
Secukinumab (Cosentyx) is an interleukin‑17A (IL‑17A) monoclonal antibody. Pregnancy planning questions usually focus on two timing issues: when to stop before trying to conceive, and what to do after conception.
The provided information doesn’t include pregnancy, fertility, or stopping-time guidance for secukinumab, so there isn’t enough detail here to give a specific “how long before” or “what to do during pregnancy” recommendation.
How long should you stop secukinumab before trying to conceive?
People planning pregnancy often ask for a washout period based on drug clearance and exposure during early development. The provided information doesn’t include secukinumab pharmacokinetics or any guideline/label statement on preconception discontinuation, so a specific timeframe can’t be supported from the information available here.
What happens if you become pregnant while on secukinumab?
A common related question is whether to stop immediately, whether switching therapies is needed, and how clinicians monitor pregnancy exposure. The provided information doesn’t include any pregnancy-exposure management details for secukinumab, so I can’t accurately describe recommended steps.
Is secukinumab compatible with breastfeeding?
Breastfeeding compatibility depends on whether and how much drug transfers into breast milk and what guidance is used for infants. The provided information doesn’t include breastfeeding-specific information for secukinumab, so I can’t confirm safety expectations.
What should people switch to when planning pregnancy?
Many pregnancy plans involve balancing two risks: medication exposure versus uncontrolled inflammatory disease (such as psoriatic arthritis, ankylosing spondylitis, or plaque psoriasis). The provided information doesn’t list pregnancy-safe alternatives or step-down strategies for secukinumab.
What risks are patients usually worried about with secukinumab in pregnancy?
When patients search this topic, concerns often include:
- fetal risk from IL‑17A blockade,
- whether continuing treatment prevents disease flares that themselves can harm pregnancy,
- timing of last dose around conception,
- and infant exposure after birth (especially if breastfeeding).
No risk estimates or labeled pregnancy findings are included in the information provided here.
Where to check the most reliable, up-to-date pregnancy guidance
For accurate, current labeling and pregnancy-related recommendations, check the prescribing information for Cosentyx and your clinician’s risk-benefit assessment for your specific condition and disease control needs.
If you want, share what country you’re in (labeling varies) and whether the goal is psoriasis, psoriatic arthritis, or ankylosing spondylitis—then I can tailor the pregnancy-planning questions you should ask your prescriber based on what’s typically covered (stop timing, disease-control plan, and infant exposure considerations).
---
Sources
No sources were provided with the question, so none could be cited.